Buy Quality SGT-151(Cumyl-PeGACLONE)




SGT-151 was specifically designed to circumvent German generic legislative approaches (NpSG) to control ‘cannabimimetics/synthetic cannabinoids’.
Nevertheless, the aim was to prohibit indole, indazole, and benzimidazole core structures in November 2016.

Buy Quality SGT-151(Cumyl-PeGACLONE)

it is not the first time that substances have been exclusively designed to evade generic definitions in national laws.SGT-151

It was reported that synthetic cannabinoid receptor agonist constituents of Spice were classified in the UK as Class B agents. This was in December 2009.

By the first quarter of 2017, Cumyl-PeGACLONE had been detected in 23% and 45% of test purchased herbal blends in Germany.

SGT-151 was detected at concentrations between 15-74 mg/g; average 39 mg/g.

As has been seen with other core structures, it is reasonable to anticipate the emergence of analogues. There is potential for modification of the structure at the R1-R5 positions, or a combination.

Reports of 5F-Cumyl-PeGACLONE are already emerging.

We postulate three other potential analogues and propose nomenclature. Other analogues are possible.

Following pharmacological evaluation, Cumyl-PeGACLONE demonstrated full agonistic activity and high potency at both CB1 and CB2 receptors. In vitro and in vivo phase I metabolism studies have shown Cumyl-PeGACLONE to be extensively metabolized.



The authors aim to report a case of surreptitious administration of a synthetic cannabinoid (SC) and the subsequent toxicological investigations to be able to document accurately the case for submission at a hearing. A dealer gave surreptitiously a substance to two juvenile migrants who experienced shakings and faintness. The laboratory received a blood sample from each of the two victims, who, according to the investigators, were probably exposed to SG, a SC, also known as CUMYL-PEGACLONE. Blood and urine specimens from the dealer, who claimed being a user of 51 were received at the same time. To characterize the metabolites of 15, the drug was incubated with a pool of human hepatic microsomes and the cofactors required to ensure the functioning of the main Phase I and Phase II enzymes. The incubation media were analyzed by liquid chromatography coupled to high-resolution mass spectrometry. The metabolites identified following transformation by hepatic microsomes were mostly N-dealkylated SGT-151, mono-hydroxylated SGT-151 and di-hydroxylated .The presence of SGT-151 (5.4 ng/mL) and its metabolite, N-dealkyl, was confirmed in the dealer’s blood. Two metabolites of (OH-SGT-151, diOH-SGT-151) were detected in the dealer’s urine. (~1 ng/mL) and its metabolite N-dealkyl  were detected in the blood samples of the two victims.


10g, 50g, 100g, 500g, 1000g

Shopping Cart
error: Content is protected !!